Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)

April 17, 2026 6:46 AM
H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Sell rating and $5.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments